Quadrant Capital Group’s Aimmune Therapeutics AIMT Stock Holding History

Quadrant Capital Group’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-12	Closed	–	–	2431
2020 Q3	$0	Buy	+12	New	+$256	﹤0.01%	2384

Quadrant Capital Group's AIMT Position: Q4 2020 in Review

Quadrant Capital Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 12 shares.

Quadrant Capital Group first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Quadrant Capital Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Quadrant Capital Group sold 12 Aimmune Therapeutics shares in Q4 2020.
Quadrant Capital Group first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Quadrant Capital Group's Aimmune Therapeutics position peaked at $0 in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Quadrant Capital Group's 13F filing for Q4 2020, filed 16 Feb 2021.